Original ArticleThe effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial
KEYWORDS
Cited by (0)
The results from this clinical trial were presented in the abstract form at the American Society of Nephrology meeting in Denver, Colorado in November 2010.
GMC is a member of the Scientific Advisory Board of DaVita Clinical Research and the Board of Directors of Satellite Healthcare. MC is a member of Baxter Healthcare Dialysis Advisory Board. TG is a consultant for Eli Lilly, Amgen, Cormedix, Keryx Biopharmaceuticals, and Nephrogenex. ASK is an investigator whose research originated in Amgen. NWL owns stock in Fresenius Medical Care North America. MVR is a consultant for Amgen and DaVita. MLU is a consultant for Baxter Healthcare, Merck, and Sigma Tau with investigator initiated research from Baxter, DCI, and Satellite Dialysis. All other authors declared no competing interests.